News

The proposal was communicated in a letter from Jeff Himawan, the chairman of MediciNova, to Zola Horovitz, the chairman of Avigen. The letter delivered to Dr Horovitz further

As part of its effort to restructure and consolidate operations, Neurogen is divesting certain non-core assets. Neurogen’s C5a patent estate and related assets were generated as part of

Dr Reddy’s will also market a generic version of the Clarinex 5mg tablet six months after the launch of the first generic version of that product. The agreements

The first step in this reorganization is the establishment of Covidien’s tax residency in Ireland in December 2008. Covidien shareholders then will be asked to vote in favor

The combined company will have a significant presence in over 60 countries and generated approximately $13.6 billion in revenues on a pro-forma basis for the 12 months ended

Dr Shebuski, a cardiovascular pharmacologist, has broad experience in cardiovascular drug development with over 25 years in the pharmaceutical industry. He will be responsible for the pre-clinical and

AVI-6002 and AVI-6003 are novel analogs based on Avi’s phosphorodiamidate morpholino oligomers antisense chemistry in which anti-viral potency is enhanced by the addition of positively-charged components to the

Under the terms of the agreement, Archemix will receive $27.5 million in upfront payments from GlaxoSmithKline (GSK), including a $6.5 million equity investment by GSK in the company.

The first was for Roche’s thyroid hormone receptor (THR) beta agonist, a clinically ready candidate for the control of cholesterol, triglyceride levels and potential in insulin sensitization/diabetes. The